LBA 18: Improvement in Survival with the Addition of Talazoparib to First-Line Enzalutamide Treatment in RR-Deficient mCRPC Patients
The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide, regardless of whether they had HRR gene alterations. In this sub-analysis, men without HRR-deficient cancers or with unknown HRR status had a modest clinical benefit.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen